LinkedIn Share Twitter Share Facebook Share Email Share

We are deeply grateful to all the patients involved in our clinical trials and the therapists who support them – our company exists to transform mental health care, and we couldn’t do it without them.

In 2021, we developed our charters: our commitments to how we will work with patients and therapists, developed with their input and reflecting their needs. Our charters are one way in which we hold ourselves accountable to working in a responsible and ethical way, with the people whose lives are being impacted by our clinical trials.

One year later, we’ve reflected on the ways in which we’ve made progress towards meeting these commitments, and the work that there is still to do. Our whole team is focused on doing more, every day, as we move closer to achieving our goal of accelerating patient access to evidence-based innovation in mental health.

Warm regards,

Ekaterina Malievskaia MD, Chief Innovation Officer and Co-founder


Our patient charter

Read about the progress we’re making towards meeting our commitments to patients, in comments from Dr Steve Levine, Senior Vice-President, Patient Access and Medical Affairs.

Steven L


  • Patient safety is our top priority, which is why we run rigorous clinical studies
  • In 2021 we completed two clinical trials: our phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression, and our exploratory study of COMP360 psilocybin therapy alongside SSRI antidepressants
  • We have learnt a huge amount from these studies, and we’re using these learnings to inform the planning for our phase 3 programme


  • We’re building an online community of people from a diverse range of backgrounds who all have personal experience of treatment-resistant depression
  • We will seek their input and listen to them, and ensure that their experiences and aspirations inform all aspects of our work


  • We have shared the topline results of all our studies on our website, alongside videos of experts explaining the results in an accessible way
  • Our healthy volunteers study was published in a peer-reviewed journal as open access, and we will do the same for our treatment-resistant depression studies once these have been published in a journal
  • In 2022 we plan to run focus groups with patients about how we’re communicating our research on our website, to make sure we’re doing so in ways that patients can understand


  • We’ve created a Patient Access and Health Systems Advisory Board with people from patient advocacy groups, healthcare providers, health systems, payors, and ethicists
  • The board has met several times over the last year to look at issues around integrating COMP360 psilocybin therapy, if approved, into health systems and how we make it accessible to everyone who might benefit from it

Our therapist charter

Read about the progress we’re making towards meeting our commitments to therapists.


  • We’ve been working with therapists to build Therapist COMPanion, an online training platform to share knowledge and create a community, complementing what we’re doing in live sessions and interactions
  • Therapist COMPanion will allow therapists to connect with their peers and engage in learning
  • Therapists will be able to listen to psilocybin therapy sessions, encouraging them to self-reflect and build their skills. They’ll also have access to training exercises, resources, and live feedback from trainers and mentors

Professional recognition

  • We’re building a programme for the training of trainers and mentors working with COMP360 psilocybin
  • We are creating a pathways for therapists to demonstrate that they have the core skills required to become a trainer and mentor for new therapists in COMP360 psilocybin therapy


  • Therapist wellbeing is a big part of our therapist mentoring programme, and we actively encourage all therapists to engage in self-care practices
  • For our phase 3 studies, all our therapists will take part in a self-care learning module on Therapist COMPanion

Diversity & inclusion

  • We have created a diversity, equity, and inclusion (DEI) advisory group that is integrated into our working groups focused on clinical model development and therapist training
  • Our goal is to use a DEI lens to inform all aspects of our work, and we plan to fund DEI-focused research in 2022, so that we can address barriers to access for marginalised groups of patients and therapists
  • We’re developing training for therapists on cultural humility and awareness to ensure that the content and tools we use to train therapists are inclusive, and to prepare therapists to engage with a diverse group of people in COMP360 psilocybin therapy sessions
LinkedIn Share Twitter Share Facebook Share Email Share